TransEnterix, Inc. (TRXC)

Shares of TRXC climbed more than 6.5% in after-hours trading Monday as the company said that it has acquired the surgical robotics division of SOFAR S.p.A., an Italian health care company, in a cash and stock transaction with total consideration of $99.8 million.

SOFAR has developed the TELELAP ALF-X(R) advanced robotic system for Minimally Invasive Surgery, which has an active CE Mark.

According to TRXC, the acquisition of SOFAR’s surgical robotics division is anticipated to have a positive financial impact going forward. TRXC believes that the ability to commercialize the ALF-X system in the near-term under the existing CE Mark and the company’s significantly expanded market opportunity could accelerate its revenue growth more than previously anticipated.

TRXC is a medical device company that is pioneering the use of robotics to improve minimally invasive surgery by addressing the economic and clinical challenges associated with current laparoscopic and robotic options.

More about TransEnterix, Inc. (TRXC) at www.transenterix.com

**

Vascular Biogenics Ltd. (VBLT)

VBLT shares rose 18.25% in regular trading Monday and surged significantly in the extended session after investment analysts at JMP Securities upgraded the company’s stock from Market Perform to Market Outperform

VBLT recently said that complete Phase 2 data on VB-111 in combination with Bevacizumab (Avastin(TM)) will be presented at the European Society for Medical Oncology’s (ESMO) European Cancer Congress 2015, being held September 25th-29th in Vienna, Austria. According to VBLT, the presentation will include response rates in patients, as well as updated results on overall survival and response rate.

VB-111 is a novel, intravenously-administered, next generation targeted anti-angiogenic agent that utilizes VBLT‘s proprietary Vascular Targeting System (VTS(TM)) to target endothelial cells in the tumor vasculature for cancer therapy. VBLT‘s VB-111 has Fast Track Designation for recurrent glioblastoma in the US and organ drug status for glioblastoma in both the US and EU.

VBLT, operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer.

More about Vascular Biogenics Ltd. (VBLT) at www.vblrx.com

**

Crown Equity Holdings Inc. (CRWE)

CRWE provides marketing solutions that boost customer awareness and merchant visibility on the Internet.

The company is currently developing its CRWE WORLD ( www.crweworld.com ), a community targeted platform which goal is to be a one-stop shop for the various needs of online consumers in a range of marketing specialties like Real Estate, Coupons & Deals, Business Directory and more

CRWE WORLD’s business model is based on selling advertising to businesses targeting their marketing message locally, nationally, internationally and also to target potential clients for an specific location, such as within a certain zip code.

The company’s CRWE Real Estate ( www.CRWERealEstate.com ) is expected to be integrated in all the CRWE WORLD Network. It will allow people to submit their listings for exposure to visitors searching for homes.

More about Crown Equity Holdings Inc. (CRWE) at www.crownequityholdings.com

**

Disclaimer: The disclaimer is to be read and fully understood before using our site, or joining our email list. CRWE PR Finance is not a registered investment adviser. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. Investors should always conduct their own due diligence with any potential investment, with independent research and other professional advice. Read Full Disclaimer at CRWE PR Finance www.finance.crwe-pr.com/disclaimer